Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice.
about
Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family CoronaviridaeRespiratory viruses other than influenza virus: impact and therapeutic advancesCoronavirus virulence genes with main focus on SARS-CoV envelope geneBroad-Spectrum Drugs Against Viral AgentsA new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivoSevere acute respiratory syndrome coronavirus as an agent of emerging and reemerging infectionA review of treatment modalities for Middle East Respiratory Syndrome.ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.Advances in antivirals for non-influenza respiratory virus infections.Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus inhibitors.Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice.Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection.Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.Japanese Encephalitis VaccinesMiddle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like diseaseSingle-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse modelIntranasal administration of dsRNA analog poly(I:C) induces interferon-α receptor-dependent accumulation of antigen experienced T cells in the airways.Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin.Inhibitors of SARS-CoV entry--identification using an internally-controlled dual envelope pseudovirion assay.Hendra and nipah infection: pathology, models and potential therapies.Emerging paramyxoviruses: molecular mechanisms and antiviral strategiesProtective role of Toll-like Receptor 3-induced type I interferon in murine coronavirus infection of macrophages.Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.Manipulation of acute inflammatory lung disease.Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle.Animal models in virus research: their utility and limitations.Nucleic acid-based drugs against emerging zoonotic viruses.Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapyMiddle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.Chloroquine for the 2019 novel coronavirus SARS-CoV-2
P2860
Q24648487-4E76AF91-12FD-4C26-BB2C-1266524D1658Q24655957-75C509BA-0FEA-427F-97AB-6890A2E7C1A9Q26827561-C7C61CC5-90B7-4E32-8A51-3271FC517455Q27487859-0726B2D5-B974-4179-80D3-D99E29338AE3Q27490484-E01E3BC3-D9C7-4DAA-8C38-0699A9FD3FF0Q28383088-B4B03E1A-5B15-4552-932E-4A37C23057F6Q30248209-3F296814-7BFA-4FC2-9D50-507E4952592DQ30404586-64DCFE6A-8282-4ED2-AE42-B9AD44667AADQ30419612-66248CEA-D0D0-4DE7-81BB-EE6E0507CC14Q30457132-0E191374-3477-417F-BA6A-3DB07ACF4EB6Q31161722-4EF4894E-2D53-443E-867C-8357DFACF4A4Q33511964-179A802B-B148-430D-837E-327BFDEADE56Q33525586-69DB62E4-4E5E-4540-885D-29C2BED35B6BQ34058365-1A6BA0DA-C2F8-4210-9BB7-4D9F074A6F66Q34466587-A8183C3B-6B4E-45F8-95C8-CEA46CC386F5Q34468689-65D54566-40A1-4D02-91B8-120A4BCBC256Q34478750-7EBCF478-F7D3-4BE0-B3F3-D9F564B5E75FQ34510913-24E5016C-A651-42C6-AB5A-AF5842C2E430Q34894092-F9D8DE5F-37BA-4CA3-955E-5265F698E084Q35499344-6D1E7278-D23C-4BC9-BEF9-EEC40287ED3EQ35658146-F08006B0-CA9F-4BD0-B032-712EA18AD9CAQ35658152-39521820-CBE4-42A1-89EA-C6D333D542AFQ36067731-1692F661-37A4-4518-A11A-954E60CD9572Q36740258-8F3B0511-02C4-45D2-B3FB-1CF8C5CB3518Q37274730-278ED2F2-C9C7-4BFB-8215-AC4C5FE63C92Q37349724-68DA4969-1C0B-498D-9F82-88D14C3E4BE1Q37481314-7760A6E8-3481-4C72-B215-342B30ED8492Q38043556-E1E11FA9-3A18-4A00-AD85-DCB2B08354AAQ38591847-A2C1235B-3E36-44E1-8DCA-CA1945A03D50Q39727842-D945EF06-646F-40AF-A779-A4788C237B7AQ43280688-1BD2385E-604E-47DB-8F4C-B60CF8B5D6EDQ86911130-4400bb6a-49fe-2dc8-6072-10d017f66ac2
P2860
Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Evaluation of immunomodulators ...... oV replication in BALB/c mice.
@en
type
label
Evaluation of immunomodulators ...... oV replication in BALB/c mice.
@en
prefLabel
Evaluation of immunomodulators ...... oV replication in BALB/c mice.
@en
P2093
P2860
P1476
Evaluation of immunomodulators ...... oV replication in BALB/c mice.
@en
P2093
Craig W Day
Dale L Barnard
Kevin Bailey
Larry Lauridsen
Matthew Heiner
Paul K S Chan
Robert Montgomery
Robert W Sidwell
P2860
P304
P356
10.1177/095632020601700505
P577
2006-01-01T00:00:00Z